WO2026058045 - ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR COMBINATION THERAPY
National phase entry is expected:
Publication Number
WO/2026/058045
Publication Date
19.03.2026
International Application No.
PCT/IB2025/000498
International Filing Date
12.09.2025
Title **
[English]
ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR COMBINATION THERAPY
[French]
INHIBITEUR D'ALPHA4BÊTA7 ET POLYTHÉRAPIE PAR INHIBITEUR D'IL-23
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
YAJNIK, Vijay
Priority Data
63/693,951
12.09.2024
US
63/826,901
19.06.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3490 | |
| EPO | Filing, Examination, Granting | 25525 | |
| Japan | Filing, Examination, Granting | 3079 | |
| South Korea | Filing, Examination, Granting | 3978 | |
| USA | Filing, Examination, Granting | 10190 |
Total:
46,262
Contact Us
Abstract[English]
Provided herein are combination therapies comprising an alpha4beta7 inhibitor, e.g., an anti-alpha4beta7 antibody, e.g., vedolizumab, and an IL-23 inhibitor, e.g., an anti-IL- 12/IL-23 antibody.[French]
L'invention concerne des polythérapies comprenant un inhibiteur d'alpha4bêta7, par exemple, un anticorps anti-alpha4bêta7, par exemple, le védolizumab, et un inhibiteur d'IL-23, par exemple, un anticorps anti-IL-12/IL-23.